


IN THE CLAIMS:

Claim 1 (previously presented) A cis-stilbene of the formula



wherein:

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are each ~~methyl~~ independently alkyl,

R<sup>4</sup> is ~~methyl; alkyl, haloalkyl, alkenyl, alkynyl, alkylthio, alkylsulphinyl, alkylsulphonyl~~  
or halo,

R<sup>5</sup> is hydrogen, ~~alkoxy, alkyl, alkylthio, hydroxy or halo,~~

or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.

Claims 2 and 3 (cancelled)

Claim 4 (previously presented) (Z)-1-(3- hydroxyl-4-methylphenyl)-2-(3,4,5-trimethoxyphenyl)ethene.

Claim 5 (previously presented) A prodrug of a cis-stilbene which is a carboxylate ester, phosphate ester, sulphate ester or carbonate of the cis-stilbene as claimed in claim 1.

Claim 6 (previously presented) A prodrug of a cis-stilbene which is a phosphate ester of a cis-stilbene according to claim 1.

Claim 7 (previously presented) A prodrug according to claim 5 which is a dihydrogen phosphate ester.

Claim 8 (previously presented) (Z)-2-methyl-5-[2-(3,4,5-trimethoxyphenyl) ethenyl]phenyl dihydrogen phosphate.

Claim 9 (previously presented) A composition for use in the destruction of neovasculature which composition contains an amount of the cis-stilbene according to claim 1 effective to destroy neovasculature and a pharmaceutically acceptable excipient.

Claim 10 (withdrawn) A method for treating neovascularisation in a patient comprising administering to a patient suffering from neovascularisation a therapeutically effective amount of a composition comprising the cis-stilbene as claimed in claim 1.

Claims 11 and 12 (cancelled)


Claim 13 (previously presented) A composition for use in the destruction of neovasculature which composition contains an amount of the prodrug according to claim 5 effective to destroy neovasculature and a pharmaceutically acceptable excipient.

Claim 14 (withdrawn) A method for treating neovascularisation in a patient comprising administering to a patient suffering from neovascularisation a therapeutically effective amount of a composition comprising the prodrug as claimed in claim 5.

Claims 15 to 19 (cancelled)

Claim 20 (previously presented) A composition for use in the destruction of neovasculature which composition contains an amount of (Z)-1-(3- hydroxyl-4-methylphenyl)-2-(3,4,5-trimethoxyphenyl)ethene or a prodrug thereof effective to destroy neovasculature and a pharmaceutically acceptable excipient.

Claim 21 (currently amended) A cis-stilbene prodrug of formula



wherein:

R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are each methyl ~~independently alkyl~~,

R<sup>4</sup> is methyl ~~alkyl, haloalkyl, alkenyl, alkynyl, alkylthio, alkylsulphinyl, alkylsulphonyl or halo,~~

R<sup>5</sup> is hydrogen, ~~alkoxy, alkyl, alkylthio, hydroxyl or halo,~~ and

X is a group which can be removed in vivo by hydrolysis.

Claims 22 to 24 (cancelled)

Claim 25 (previously presented) A cis-stilbene prodrug according to claim 21 which is a carboxylic ester, phosphate ester, sulphate ester or carbonate.

Claim 26 (previously presented) A cis-stilbene prodrug according to claim 21 which is a phosphate ester.

Claim 27 (previously presented) A prodrug according to claim 25 which is a dihydrogen phosphate ester.

Claim 28 (cancelled)

Claim 29 (previously presented) A composition for use in the destruction of neovasculature which composition contains an effective amount of the cis-stilbene prodrug according to claim 21 and a pharmaceutically acceptable excipient.

Claim 30 (previously presented) A composition as claimed in claim 29 in combination with at least one further anti-tumour substance.

Claims 31 and 32 (cancelled)

Claim 33 (previously presented) A composition for use in the destruction of neovasculature which composition contains an effective amount of the prodrug according to claim 25 and a pharmaceutically acceptable excipient.

Claim 34 (previously presented) A composition for use in the destruction of neovasculature which composition contains an effective amount of the cis-stilbene prodrug according to claim 26 and a pharmaceutically acceptable excipient.

Claim 35 (previously presented) A composition for use in the destruction of neovasculature which composition contains an effective amount of the cis-stilbene prodrug according to claim 27 and a pharmaceutically acceptable excipient.

Claim 36 (previously presented) A composition for use in the destruction of neovasculature composition contains an effective amount of the cis-stilbene dihydrogen phosphate according to claim 28 and a pharmaceutically acceptable excipient.

Claim 37 (withdrawn) A method of treatment of a disease involving neovascularisation comprising the administration of an effective amount of a cis-stilbene prodrug as claimed in claim 21.

Claim 38 (withdrawn) A method according to claim 37 wherein the disease is cancer involving a solid tumour.

Claim 39 (withdrawn) A method according to claim 38 wherein said cis-stilbene prodrug is administered in combination with radiotherapy or another anti-tumor substance.

Claim 40 (withdrawn) A method according to claim 37 wherein the disease is a disease of the eye.

Claim 41 (withdrawn) A method according to claim 37 wherein the cis-stilbene prodrug is (Z)-2-methyl-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate.

Claim 42 (withdrawn) A method of treating neovascularisation in a patient comprising administering to a patient suffering from neovascularisation a therapeutically effective amount of a composition comprising a compound according to claim 4.

Claim 43 (withdrawn) A method of treating neovascularisation in a patient comprising administering to a patient suffering from neovascularisation a therapeutically effective amount of a composition comprising a dihydrogen phosphate ester of a compound according to claim 4.

Claim 44 (withdrawn) A method according to claim 42 wherein neovascularisation of the eye is treated.

Claim 45 (withdrawn) A method according to claim 43 wherein neovascularisation of the eye is treated.